TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Clinical trials for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOID CARDIOMYOPATHY trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to slow rare heart disease by targeting toxic proteins
Disease control OngoingThis study tests an investigational drug called eplontersen in 64 Chinese adults with transthyretin amyloid cardiomyopathy, a condition where abnormal proteins build up in the heart. The goal is to see if eplontersen can safely lower those protein levels compared to a placebo ove…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New drug aims to clear Heart-Clogging proteins in fatal condition
Disease control OngoingThis study tests an experimental drug called ALXN2220 in adults with a heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM), where abnormal proteins build up in the heart and make it weak. About 1,181 participants will receive either the drug or a placebo to see …
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Bronx study sheds light on underdiagnosed heart condition in diverse groups
Knowledge-focused OngoingThis study created a database of 476 patients in the Bronx who were tested for a serious, often undiagnosed heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). Researchers collected medical records from 2014 to 2023 to track who was diagnosed, their health outc…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Sponsor: Montefiore Medical Center • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC